Recent research into rituximab-induced serum sickness (RISS) reinforces the understanding that patients generally recover quickly. However, the study also found patients with autoimmune disease, especially SLE, had a significantly higher risk for developing RISS than patients using rituximab to treat hematological malignancy…
Technology, billing, regulations—how do rheumatologists manage the business side of their practices in an ever-changing environment? During this year’s Annual Meeting, a practical, full-day workshop will offer attendees the tools to thrive in today’s healthcare business landscape…
Arwen Pieterse, PhD, and colleagues urge all physicians to allocate more meaningful time to collaborate in shared decision making with patients, without compromising access or productivity…
Although not a first-line treatment, autologous serum tears are often used as a treatment option for dry eyes related to both ophthalmic and rheumatic conditions. Recent research into its efficacy also evaluated the treatment’s patient satisfaction, finding autologous serum tears reduced symptoms of dry eye disease and received high patient satisfaction scores…
A new study adds to the evidence that metabolic factors play an important role in the pathogenesis of rheumatoid arthritis (RA). In this large, prospective cohort study, Liu et al. found that increased physical activity among women was associated with a reduced risk of RA…
Research shows filgotinib may be safe and effective for treating rheumatoid arthritis. The drug’s manufacturer is expected to be submit a new drug application for filgotinib to the FDA in 2019…
NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis. “This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA…
(Reuters)—The Trump administration is appealing a court ruling that struck down its plan to compel pharmaceutical companies to disclose wholesale prices of their drugs in televisions advertisements. The U.S. Department of Health and Human Services (HHS) filed a notice of appeal on Wednesday, as it prepares to challenge the July federal court ruling. “If the…